Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BMS-986166 in Healthy Subjects
NCT02790125Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of udifitimod in ulcerative colitis (UC) and atopic dermatitis (AD) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of All Adverse Events, Incidence of Serious Adverse Events and 9 more. Started Jul 2016; status: completed.
02
Drugs
udifitimod
03
Conditions
ulcerative colitis (UC)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02790125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790125.